EZH2 and precursor B-cell acute lymphoblastic leukemia: The new gene targets such as BTLA, CD200, VPREB1 which are associated with inferior event-free and overall survival; DMD with relapse, TBL1XR1 and TP53 with chemo-resistance; EZH2, PAR1 region, and P2RY8-CRLF2 with poor prognosis; CASP8AP2, NF1, and SUZ12 associated with poor response to induction therapy are included in this dMLPA panel and useful for further risk stratification in cytogenetically good risk B-ALL cases.